Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 1, 2006, Pages 53-61

  Capela, João Paulo ^a   Meisel, Andreas ^b   Abreu, Artur Reis ^c   Branco, Paula Sério ^c   Ferreira, Luísa Maria ^c   Lobo, Ana Maria ^c   Remião, Fernando ^a   Bastos, Maria Lurdes ^a   Carvalho, Félix ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 (GLUTATHION S YL) ALPHA METHYLDOPAMINE; ALPHA METHYLDOPAMINE; DOPAMINE DERIVATIVE; N METHYL ALPHA METHYLDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO; HYPERTHERMIA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TEMPERATURE DEPENDENCE;

ACETYLCYSTEINE; ACRIDINE ORANGE; ANIMALS; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETHIDIUM; FEVER; FLUORESCENT DYES; HALLUCINOGENS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; RATS; RATS, WISTAR;

EID: 29244463299     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.092577     Document Type: Article

References (38)

1. Bai F, Lau SS, and Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol 12:1150-1157.
2. Bindoli A, Rigobello MP, and Deeble DJ (1992) Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 13:391-405.
3. Bolton JL, Trush MA, Penning TM, Dryhurst G, and Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160.
4. Borgman RJ, Baylor MR, McPhillips JJ, and Stitzel RE (1974) α-Methyldopamine derivatives. Synthesis and pharmacology. J Med Chem 17:427-430.
5. Carvalho M, Milhazes N, Remião F, Borges F, Fernandes E, Monks T, Amado F, Carvalho F, and Bastos ML (2004a) Hepatotoxicity of 3,4-methylenedioxyamphetamine and α-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 78:16-24.
6. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Carvalho F, and Bastos ML (2004b) The toxicity of N-methyl-α-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 200:193-203.
7. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Monteiro MC, Gonçalves MJ, Seabra V, Amado F, Carvalho F, and Bastos ML (2004c) Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem Res Toxicol 17:623-632.
8. Chu T, Kumagai Y, DiStefano EW, and Cho AK (1996) Disposition of methylenodioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796.
9. Colado MI, O'Shea E, Granados R, Murray TK, and Green AR (1997) In vivo evidence for free radical involvement in 5-HT following administration of MDMA ("ecstasy") and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121:889-900.
10. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, and Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338-345.
11. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, and Colado MI (2001) 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154:251-260.
12. García-Repetto R, Moreno E, Soriano T, Jurado C, Gimenez MP, and Menendez M (2003) Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 135:110-114.
13. Green AR, Mechan AO, Elliot JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55:463-508.
14. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623.
15. Henry JA (1992) Ecstasy and the dance of death. Br Med J 305:5-6.
16. Hiramatsu M, Kumagai Y, Unger SE, and Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-527.
17. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, and Monks TJ (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422-431.
18. Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, and Kaplowitz N (1990) Evidence for carrier mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Investig 85:2009-2013.
19. Kleiner HE, Rivera MI, Pumford NR, Monks TJ, and Lau SS (1998) Immunochemical detection of quinol-thioether-derived covalent protein adducts. Chem Res Toxicol 11:1283-1290.
20. Kumagai Y, Lin LY, Schmitz DA, and Cho AK (1991) Hydroxyl radical mediated demethylenation of (methylenedioxy)-phenyl compounds. Chem Res Toxicol 4:330-334.
21. Lautenschlager M, Onufriev MV, Gulyaeva NV, Harms C, Freyer D, Sehmsdorf US, Ruscher K, Moiseeva YV, Arnswald A, et al. (2000) Role of nitric oxide in the ethylcholine aziridinium (AF64A) model of delayed apoptotic neurodegeneration in vivo and in vitro. Neuroscience 97:383-393.
22. Lim HK and Foltz RL (1988) In vivo and in vitro metabolism of 3,4-(methylenedioxy) methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol 1:370-378.
23. Miller RT, Lau SS, and Monks TJ (1995) Metabolism of 5-(GSyl)-α- methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem Res Toxicol 8:634-641.
24. Miller RT, Lau SS, and Monks TJ (1996) Effect of 5-(GSyl)-α- methyldopamine on dopamine, serotonin and norepinephrine concentrations following intracerebroventricular administration to male Sprague-Dawley rats. Chem Res Toxicol 9:457-465.
25. Miller RT, Lau SS, and Monks TJ (1997) 2,5-Bis-(GSyl)-α- methyldopamine, a putative metabolite of (±)-3,4- methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-180.
26. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-methylenodioxyamphetamine 3,4-methylenodioxymethamphetamine (Ecstasy) toxicity. Ther Drug Monit 26:132-136.
27. Paris JM and Cunningham KA (1992) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res Bull 28:115-119.
28. Parrott AC (2002) Recreational Ecstasy/MDMA, the serotonin syndrome and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837-844.
29. Parrott AC (2005) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19:71-83.
30. Remião F, Carvalho M, Carmo H, Carvalho FD, and Bastos ML (2002) Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem Res Toxicol 15:861-869.
31. Ricaurte GA, Yuan J, and McCann UD (2000) (±)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10.
32. Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974:127-133.
33. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, and de La Torre R (2001) 3,4- Dihydroxymetamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208.
34. Simantov R and Tauber M (1997) The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB J 11:141-146.
35. Sprague JE and Nichols DE (1995) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273:667-673.
36. Stumm G, Schlegel J, Schafer T, Wurz C, Mennel HD, Krieg JC, and Vedder H (1999) Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J 13:1065-1072.
37. Yeh SY (1999) N-tert-Butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse 31:169-177.
38. Zhang F and Dryhurst G (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37:1084-1098.